跳至主要内容
临床试验/CTRI/2025/10/095814
CTRI/2025/10/095814尚未招募2 期

An Open Label Single Arm Clinical Study to Evaluate The Efficacy of Shatavaryadi Ghrita in Asrigdara w.s.r. Dysfunctional Uterine Bleeding

Dr Shivangi Yadav1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年1月1日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
30
试验地点
1
主要终点
Efficacy of Shatavaryadi Ghruta in asrugdara could me more as compared to any other drug.

研究概览

简要总结

Now a days due to change in lifestyle menstrual issues are the major problems faced by females. Soo as per the OPD prevalence it was observed that asrigdara found to be observed very frequent disease in females of age 18 to 45 yrs married female with no comorbidities Shatavaryadi ghruta in 30 patients was planned to give as per diagnostic, inclusion and exclusion criteria as an open lable single arm clinical study to evaluate the efficasy of Shatavaryadi ghrita in Asrugdara.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 45.00 Year(s)(—)
性别
Female

入选标准

  • Patient presenting with excessive, prolonged menstrual bleeding, intermenstrual bleeding for 2 months irrespective of parity married female complaint of menorhagia from 3 cycles or more than 3 cycle.

排除标准

  • unmarried below 18 and above 45 yrs of age on going research study recent abortion, anemia, tb, hypertension, dm, hypo or hyperthyroidism, cardiac disease, renal parynchymal disease, jaundice, benign or malignant growth, cervical errosion, cervical polyp, pid, pterovaginal prolapse, endometriosis, h/o IUD.

结局指标

主要结局

Efficacy of Shatavaryadi Ghruta in asrugdara could me more as compared to any other drug.

时间窗: The effect can be seen in 4 to 8 weeks

次要结局

  • ALONG WITH ASRIGDARA IMPROVEMENT OF OTHER YONIVYAPAD MAY IMPROVE(3 MONTHS)

研究者

发起方
Dr Shivangi Yadav
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Shivangi Yadav

Shri Babu Singh Jay Singh Ayurvedic Medical College and Hospital

研究点 (1)

Loading locations...

相似试验